Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Risedronate sodium

Brand: 
NICE TA: 464
Indication: Osteoporosis (NICE TA464)
Disease category: Endocrine system
Commissioning responsibility: CCG
PbR excluded: No

Background

Oral bisphosphonates (alendronic acid, ibandronic acid and risedronate sodium) are recommended as options for treating osteoporosis in adults only if:

•the person is eligible for risk assessment as defined in NICE’s guideline on osteoporosis (recommendations 1.1 and 1.2) and
•the 10‑year probability of osteoporotic fragility fracture is at least 1%.

Intravenous bisphosphonates (ibandronic acid and zoledronic acid) are recommended as options for treating osteoporosis in adults only if:

•the person is eligible for risk assessment as defined in NICE’s guideline on osteoporosis (recommendations 1.1 and 1.2) and
•the 10‑year probability of osteoporotic fragility fracture is at least 10% or
•the 10‑year probability of osteoporotic fragility fracture is at least 1% and the person has difficulty taking oral bisphosphonates (alendronic acid, ibandronic acid or risedronate sodium) or these drugs are contraindicated or not tolerated

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Green

Green

Green

Green

Green

Green